Abstract

Simultaneous, rapid, and quantitative detection of multiple tumor markers is extremely important for the prevention and early diagnosis of cancers. In this study, we established a microfluidic-based indirect competitive chemiluminescence enzyme immunoassay for simultaneous detection of cancer antigen 15-3 (CA15-3) and progesterone receptor membrane components 1 (PGRMC1) for diagnosis of breast cancer. CA15-3 and PGRMC1 could be simultaneously detected on the chip. On the chip, the linear ranges of CA15-3 and PGRMC1 were 10 pg/mL–100 ng/mL and 20 pg/mL–358 ng/mL, respectively, whereas the limits of detection (LOD) of CA15-3 and PGRMC1 were 3 pg/mL and 5 pg/mL, respectively. Compared with the enzyme-linked immunosorbent assay (ELISA, LOD = 20 pg/mL for CA15-3; LOD = 10 pg/mL for PGRMC1), our method could simultaneously detect multiple samples with higher sensitivity, which could greatly improve the detection efficiency and meet the requirement for early diagnosis of breast cancer.

摘要

同时、快速、定量地检测多种肿瘤标志物对于癌症的预防和早期诊断极为重要。在这项研究中，我们建立了一种基于微流控的间接竞争性化学发光酶免疫测定法，用于同时检测癌症抗原 15-3 (CA15-3) 和孕激素受体膜成分 1 (PGRMC1) 以诊断乳腺癌。芯片上可以同时检测到CA15-3和PGRMC1。在芯片上，CA15-3 和 PGRMC1 的线性范围分别为 10 pg/mL–100 ng/mL 和 20 pg/mL–358 ng/mL，而 CA15-3 和 PGRMC1 的检测限 (LOD)分别为 3 pg/mL 和 5 pg/mL。与酶联免疫吸附试验（ELISA，CA15-3 LOD = 20 pg/mL；PGRMC1 LOD = 10 pg/mL）相比，